- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02293265
Cross-sectional Study for Identification and Description of Severe Asthma Patients
Identification and Description of Severe Asthma Patients in a Cross-sectional Study-the IDEAL Study
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australië, 2450
- GSK Investigational Site
-
-
-
-
Alberta
-
Sherwood Park, Alberta, Canada, T8H 0N2
- GSK Investigational Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
- GSK Investigational Site
-
Burlington, Ontario, Canada, L7N 3V2
- GSK Investigational Site
-
Grimsby, Ontario, Canada, L3M1P3
- GSK Investigational Site
-
London, Ontario, Canada, N6A1V2
- GSK Investigational Site
-
Mississauga, Ontario, Canada, L5A 3V4
- GSK Investigational Site
-
St-Charles-Borromée, Ontario, Canada, J6E 2B4
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 1E2
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 3A9
- GSK Investigational Site
-
Windsor, Ontario, Canada, N8X2G1
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
- GSK Investigational Site
-
Quebec City, Quebec, Canada, G1V 4M6
- GSK Investigational Site
-
Québec, Quebec, Canada, G1V 4G5
- GSK Investigational Site
-
Trois Rivières, Quebec, Canada, G8T 7A1
- GSK Investigational Site
-
-
-
-
-
Berlin, Duitsland, 13086
- GSK Investigational Site
-
Berlin, Duitsland, 10717
- GSK Investigational Site
-
Berlin, Duitsland, 13597
- GSK Investigational Site
-
Berlin, Duitsland, 12203
- GSK Investigational Site
-
Berlin, Duitsland, 12157
- GSK Investigational Site
-
Hamburg, Duitsland, 22299
- GSK Investigational Site
-
-
Bayern
-
Gauting, Bayern, Duitsland, 82131
- GSK Investigational Site
-
Muenchen, Bayern, Duitsland, 80539
- GSK Investigational Site
-
-
Brandenburg
-
Cottbus, Brandenburg, Duitsland, 03050
- GSK Investigational Site
-
-
Sachsen
-
Leipzig, Sachsen, Duitsland, 04357
- GSK Investigational Site
-
Leipzig, Sachsen, Duitsland, 04103
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Duitsland, 23552
- GSK Investigational Site
-
Schleswig, Schleswig-Holstein, Duitsland, 24837
- GSK Investigational Site
-
-
-
-
-
Bayonne cedex, Frankrijk, 64109
- GSK Investigational Site
-
Dijon Cedex, Frankrijk, 21033
- GSK Investigational Site
-
Grenoble cedex 9, Frankrijk, 38043
- GSK Investigational Site
-
Lille Cedex, Frankrijk, 59037
- GSK Investigational Site
-
Lyon cedex 04, Frankrijk, 69317
- GSK Investigational Site
-
Marseille cedex 03, Frankrijk, 13331
- GSK Investigational Site
-
Nantes cedex 1, Frankrijk, 44093
- GSK Investigational Site
-
Nantes cedex 2, Frankrijk, 44277
- GSK Investigational Site
-
Paris Cedex 18, Frankrijk, 75877
- GSK Investigational Site
-
Pessac cedex, Frankrijk, 33604
- GSK Investigational Site
-
Reims Cedex, Frankrijk, 51092
- GSK Investigational Site
-
Rouen Cedex, Frankrijk, 76031
- GSK Investigational Site
-
Strasbourg, Frankrijk, 67091
- GSK Investigational Site
-
Tarbes cedex 9, Frankrijk, 65013
- GSK Investigational Site
-
Villefranche sur Saône, Frankrijk, 69655
- GSK Investigational Site
-
-
-
-
-
Birmingham, Verenigd Koninkrijk, B15 2WB
- GSK Investigational Site
-
Birmingham, Verenigd Koninkrijk, B18 7QH
- GSK Investigational Site
-
Cambridge, Verenigd Koninkrijk, CB2 2XY
- GSK Investigational Site
-
Crawley, Verenigd Koninkrijk, RH10 7DX
- GSK Investigational Site
-
Liverpool, Verenigd Koninkrijk, L12 2AP
- GSK Investigational Site
-
London, Verenigd Koninkrijk, SW17 0RE
- GSK Investigational Site
-
Middlesbrough, Verenigd Koninkrijk, TS4 3BW
- GSK Investigational Site
-
Radstock, Bath, Verenigd Koninkrijk, BA3 2UH
- GSK Investigational Site
-
Salford, Verenigd Koninkrijk, M6 8HD
- GSK Investigational Site
-
Trowbridge, Verenigd Koninkrijk, BA14 9AR
- GSK Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- GSK Investigational Site
-
-
California
-
Fresno, California, Verenigde Staten, 93720
- GSK Investigational Site
-
Los Angeles, California, Verenigde Staten, 90025
- GSK Investigational Site
-
Newport Beach, California, Verenigde Staten, 92663
- GSK Investigational Site
-
Riverside, California, Verenigde Staten, 92506
- GSK Investigational Site
-
Rolling Hills Estates, California, Verenigde Staten, 90274
- GSK Investigational Site
-
San Diego, California, Verenigde Staten, 92123
- GSK Investigational Site
-
Upland, California, Verenigde Staten, 91786
- GSK Investigational Site
-
-
Florida
-
Tallahassee, Florida, Verenigde Staten, 32308
- GSK Investigational Site
-
-
Kentucky
-
Owensboro, Kentucky, Verenigde Staten, 42301
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21236
- GSK Investigational Site
-
Columbia, Maryland, Verenigde Staten, 21044
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55402
- GSK Investigational Site
-
Plymouth, Minnesota, Verenigde Staten, 55441
- GSK Investigational Site
-
-
New York
-
Corning, New York, Verenigde Staten, 14830
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28277
- GSK Investigational Site
-
Shelby, North Carolina, Verenigde Staten, 28150
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45231
- GSK Investigational Site
-
-
Oregon
-
Medford, Oregon, Verenigde Staten, 97504
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15241
- GSK Investigational Site
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29615
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- At least 12 years of age at study visit.
- Participants eligible for enrolment and entry into the study must meet the following definition of severe asthma, which is based on the definition of severe asthma described in the European Respiratory Society/ American Thoracic Society (ERS/ATS) Guidelines for severe asthma: Asthma which requires treatment with guideline suggested medications for Global Initiative for Asthma (GINA) steps 4-5 asthma for the previous year (i.e., at least 12 months).
Patients must be treated with high dose ICS PLUS at least one of the following: LABA, leukotriene modifier, theophylline, or continuous or near continuous systemic corticosteroid (i.e., maintenance systemic corticosteroid for ≥50% of the previous year).
SPECIAL CIRCUMSTANCE: If patient is on a fixed dose combination medication, then the maximum recommended dose of the ICS/LABA combination per local label is acceptable.
- Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Participants must be able to read, comprehend, and write at a level sufficient to complete study related materials. A parent or legal guardian must provide informed consent for participants less than 18 years of age at study visit (or less than minimum age to be considered an adult per local laws).
Exclusion Criteria:
Participants who have participated in an interventional clinical trial for asthma within the past 12 months prior to Visit 1 (NOTE: subjects participating in an observational study where an investigational product or procedure is not administered will not be subject to this exclusion criteria)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Ander: Non-drug interventional group
All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires.
No investigational product will be administered to participants.
|
Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of severe asthma patients eligible for one or more biologic treatments for asthma
Tijdsspanne: Day 1
|
Biologic treatments for asthma will include mepolizumab (anti-Interleukin [IL] 5), omalizumab (anti-immunoglobulin E [IgE]), and reslizumab (anti-IL5).
|
Day 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Mean and median frequency of planned and unplanned asthma-related healthcare resource utilization in the prior 12 months
Tijdsspanne: Day 1
|
Day 1
|
|
Mean and median Charlson Comorbidity Index score
Tijdsspanne: Day 1
|
The Charlson Comorbidity Index is a score that is based on age and the presence of 19 comorbidities.
The mean and median Charlson Comorbidity Index score will be calculated and reported
|
Day 1
|
Mean pre-bronchodilator forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean post-bronchodilator FEV1/FVC ratio
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean pre-bronchodilator FEV1
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean post-bronchodilator FEV1
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean pre-bronchodilator FVC
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean post-bronchodilator FVC
Tijdsspanne: Day 1
|
Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility
|
Day 1
|
Mean and median levels of blood eosinophils
Tijdsspanne: Day 1
|
Day 1
|
|
Mean and median levels of total IgE
Tijdsspanne: Day 1
|
Day 1
|
|
Mean and median levels of specific IgE
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for asthma Control Questionnaire (ACQ-5)
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for St. George's Respiratory Questionnaire (SGRQ)
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for Asthma Quality of Life Questionnaire (AQLQ-S)
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for EuroQol 5D (EQ-5D-5L)
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for Work Productivity and Activity Impairment Index: General Health (WPAI-GH)
Tijdsspanne: Day 1
|
Day 1
|
|
Descriptive statistics for Asthma Symptom Utility Index (ASUI)
Tijdsspanne: Day 1
|
Day 1
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Nelsen LM, Cockle SM, Gunsoy NB, Jones P, Albers FC, Bradford ES, Mullerova H. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. J Asthma. 2020 Sep;57(9):1006-1016. doi: 10.1080/02770903.2019.1630640. Epub 2019 Jun 28.
- Mullerova H, Cockle SM, Gunsoy NB, Nelsen LM, Albers FC. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study. J Asthma. 2021 Apr;58(4):459-470. doi: 10.1080/02770903.2019.1708095. Epub 2020 Jan 9.
- Albers FC, Mullerova H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018 Feb;55(2):152-160. doi: 10.1080/02770903.2017.1322611. Epub 2017 Jun 16.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 201722
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Short Acting Beta Agonist (SABA)
-
AstraZenecaBeëindigdAstmaDuitsland, Spanje, Verenigd Koninkrijk, Korea, republiek van, Canada, Polen, Australië, Taiwan, Hongarije, Oekraïne
-
NovartisVoltooid
-
Henning BundgaardVoltooidChronisch hartfalen met verminderde ejectiefractie (HFrEF)Australië, Denemarken
-
Daping Hospital and the Research Institute of Surgery...VoltooidChronische obstructieve longziekteChina
-
National and Kapodistrian University of AthensBeëindigd
-
Institut für Klinische Krebsforschung IKF GmbH...EUSA Pharma, Inc.Werving
-
Royan InstituteOnbekendOnvruchtbaarheidIran, Islamitische Republiek
-
Washington University School of MedicineNational Institutes of Health (NIH); National Center for Advancing Translational...WervingAstma bij kinderen | Niet-naleving, medicatieVerenigde Staten
-
Washington University School of MedicineNational Institutes of Health (NIH); National Center for Advancing Translational...WervingAstma | Niet-naleving, medicatieVerenigde Staten
-
NovartisSchering-PloughVoltooidCOPDFrankrijk, Duitsland, België, Italië, Kalkoen, Hongarije, Argentinië, Peru, Verenigd Koninkrijk, Zuid-Afrika, Letland, Litouwen, Roemenië, Chili, Ierland, Noorwegen, Polen